孕早期超声筛查胎儿先天性心脏病的策略评估
这项大型回顾性研究纳入74 839例连续混合风险妊娠(77 396个胎儿),评估标准化孕早期超声筛查策略对胎儿先天性心脏病(CHD)的检出效能。结果显示CHD检出率为70.52%,灵敏度70.52%、特异度99.99%;作者推荐使用该策略,但强调其不应替代孕中期胎儿超声心动图。
要点
- 孕早期标准化超声筛查胎儿CHD检出率为70.52%,灵敏度70.52%、特异度99.99%。
- 无超声软指标异常且无心脏外畸形的胎儿中,CHD检出率为45.79%(185/404)。
- 作者推荐使用该筛查策略,但指出其不应替代孕中期胎儿超声心动图。
核心结论
- 孕早期超声筛查胎儿CHD可实现更早的产前诊断与咨询,本研究的标准化筛查策略检出率高,作者推荐使用该策略。
- 作者同时指出,孕早期超声筛查胎儿CHD不应替代孕中期胎儿超声心动图。
研究设计与样本
- 本研究为大型回顾性研究,纳入74 839例连续混合风险妊娠(77 396个胎儿)。
- 2015年1月至2023年6月在一家中心于孕11+0至13+6周进行常规超声扫描,采用预定义的标准化超声扫描策略并调整成像参数,评估内容包括胎儿心脏。
- 记录并分析超声结果(如心脏外先天畸形)、超声软指标(如颈项透明层增厚、静脉导管a波反向和三尖瓣反流)、随访、基因检测及诊断结果。
主要发现
- 共831例CHD,发生率为1.07%(831/77 396)。
- 孕早期扫描诊断CHD 590例胎儿,其中4例在后来的检查中确认正常;另漏诊245例。
- 检出率为70.52%,灵敏度、特异度、假阳性率和假阴性率分别为70.52%、99.99%、0.01%和29.48%。
- 超声软指标阴性且无心脏外畸形的胎儿中,CHD检出率为45.79%(185/404)。
- 281例进行了核型分析和染色体微阵列(245个胎儿)或全外显子组测序(36个胎儿),38.79%(109/281)基因检测结果阳性;273/831例CHD合并心脏外畸形。
关键数值与推荐
- CHD发生率1.07%(831/77 396)。
- 孕早期超声筛查CHD检出率70.52%,灵敏度70.52%、特异度99.99%、假阳性率0.01%、假阴性率29.48%。
- 超声软指标阴性且无心脏外畸形者CHD检出率45.79%(185/404)。
- 基因检测阳性率38.79%(109/281);CHD合并心脏外畸形273/831例。
临床怎么用
- 作者推荐使用本研究的标准化孕早期胎儿心脏筛查策略,认为其有助于CHD的早期诊断。
- 作者指出孕早期超声筛查胎儿CHD不应替代孕中期胎儿超声心动图。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the performance of a standardized first-trimester ultrasound screening strategy for fetal congenital heart disease (CHD). METHODS: This was a large retrospective study involving 74 839 consecutive mixed-risk pregnancies (77 396 fetuses). Routine ultrasound scans at 11 + 0 to 13 + 6 weeks' gestation were performed in a single center from January 2015 to June 2023. All fetuses were examined using a predefined standardized ultrasound scanning strategy with adjustment of imaging parameters, which included assessment of the fetal heart. The ultrasound results (e.g. extracardiac congenital malformations), ultrasound markers (e.g. nuchal translucency thickening, reversed a-wave in the ductus venosus and tricuspid regurgitation), follow-up, genetic tests and diagnostic results were recorded and analyzed. RESULTS: In total, there were 831 cases of CHD, with an incidence of 1.07% (831/77 396). In the first-trimester scan, 590 fetuses were diagnosed with CHD, but four were confirmed as normal in later examinations. In addition, 245 cases were missed. The detection rate was 70.52%, with a sensitivity, specificity, false-positive rate and false-negative rate of 70.52%, 99.99%, 0.01% and 29.48%, respectively. In fetuses with negative ultrasound markers and no extracardiac malformations, the detection rate of CHD was 45.79% (185/404). There were 281 cases that underwent karyotyping and chromosomal microarray (245 fetuses) or whole-exome sequencing (36 fetuses). In total, 38.79% (109/281) had a positive genetic test result. There were 273/831 CHD cases associated with extracardiac malformations. The abnormal image patterns and abnormal features of each view in the scanning strategy were summarized. CONCLUSIONS: Ultrasound screening for fetal CHD in the first trimester of pregnancy enables earlier prenatal diagnosis and consultation. The standardized ultrasound screening strategy used in this study had a high detection rate for fetal CHD in the first trimester. Our proposed fetal heart screening strategy shows promising effectiveness for early diagnosis of CHD and we recommend its use. It is important to note, however, that first-trimester ultrasound screening for fetal CHD should not replace fetal echocardiography in the second trimester. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Yang S, Qin G, He G, et al. Evaluation of first-trimester ultrasound screening strategy for fetal congenital heart disease. Ultrasound Obstet Gynecol. 2025. PMID: 40019943. doi:10.1002/uog.29186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。